<DOC>
	<DOCNO>NCT01058993</DOCNO>
	<brief_summary>This initial study determine CXCR4 inhibitor AMD 3100 plerixafor may potential treatment neutropenia due CXCR4 mutation , myelokathexis WHIM ( wart , hypogammaglobulinemia , immunodeficiency myelokathexis ) syndrome . This initial study concept involve 6 patient receive increase dos plerixafor administer subcutaneously alternate day basis . It unknown patient highly sensitive blockade CXCR4 activity release white blood cell normal volunteer cancer patient give dose drug . Therefore dose begin level 12 fold less currently use mobilize stem cell increase stepwise achieve acceptable circulate level neutrophil .</brief_summary>
	<brief_title>AMD 3100 Treatment Myelokathexis</brief_title>
	<detailed_description>This open label , single Center , phase I study examine hematological effect , pharmacokinetics safety plerixafor patient myelokathexis attributable mutation CXCR4 , utilize serial , escalate dos plerixafor administer day 1 , 3 , 5 , 8 , 10 . Five intrapatient escalate dose level , 20 microgram per kilogram ( mcg/kg ) , 40 micrograms/kilogram ( mcg/kg ) , 80 micrograms/kilogram ( mcg/kg ) , 240 micrograms/kilogram ( mcg/kg ) examine . The subject patient University Washington General Clinical Research Center 10 day ; study require subject available 14 day . Patients monitor hematological effect plerixafor observed adverse effect . If normal blood neutrophil count achieve maintain least 24 hour prior high dose , stop level .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>age 18 year , WBC ( white blood count ) less 3.0 x 10^9 per Liter , Absolute neutrophil count le 2.0 x 10^9 per Liter , platelets great 100 x 10^6 per Liter , creatinine le 2.0/milligrams per/deciliter , Creatinine clearance &gt; 60 ml/min calculate , Aspartate AminotransferaseGOT ( SGOT ) , Alanin AminotransferaseGPT ( SGPT ) , bilirubin &lt; 2.5 upper limit normal , Eastern Cooperative Oncology Group ( ECOG ) status 0 1 , mutation identify confirmed CXCR4 , granulocytecolony stimulate factor ( GCSF ) , granulocytemacrophagecolony stimulate factor ( GMCSF ) within 3 week study drug patient sign consent , accept contraception great 18 year age , sensitivity plerixafor , pregnant , prisoner , decisionally impaired , judge unlikely comply , illness may interfere interpretation result , leukemia , malignancy , active infection require antibiotic within one week study drug administration , history cardiac conduction electrocardiogram ( EKG ) abnormality , previous experimental therapy within one week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>myelokathexis</keyword>
	<keyword>WHIM syndrome</keyword>
	<keyword>AMD 3100</keyword>
	<keyword>plerixafor</keyword>
	<keyword>Myelokathexis syndrome</keyword>
	<keyword>Neutropenia due mutation CXCR-4</keyword>
</DOC>